E-resources
-
Juric, Dejan; Krop, Ian; Ramanathan, Ramesh K; Wilson, Timothy R; Ware, Joseph A; Sanabria Bohorquez, Sandra M; Savage, Heidi M; Sampath, Deepak; Salphati, Laurent; Lin, Ray S; Jin, Huan; Parmar, Hema; Hsu, Jerry Y; Von Hoff, Daniel D; Baselga, José
Cancer discovery, 07/2017, Volume: 7, Issue: 7Journal Article
Taselisib is a potent and selective tumor growth inhibitor through PI3K pathway suppression. Thirty-four patients with locally advanced or metastatic solid tumors were treated (phase I study, modified 3+3 dose escalation; 5 cohorts; 3-16 mg taselisib once-daily capsule). Taselisib pharmacokinetics were dose-proportional; mean half-life was 40 hours. Frequent dose-dependent, treatment-related adverse events included diarrhea, hyperglycemia, decreased appetite, nausea, rash, stomatitis, and vomiting. At 12 and 16 mg dose levels, dose-limiting toxicities (DLT) were observed, with an accumulation of higher-grade adverse events after the cycle 1 DLT assessment window. Pharmacodynamic findings showed pathway inhibition at ≥3 mg in patient tumor samples, consistent with preclinical -mutant tumor xenograft models. Confirmed response rate was 36% for -mutant tumor patients with measurable disease 5/14: 4 breast cancer (3 patients at 12 mg); 1 non-small cell lung cancer, where responses started at 3 mg, and 0% in patients with tumors without known hotspot mutations (0/15). Preliminary data consistent with preclinical data indicate increased antitumor activity of taselisib in patients with -mutant tumors (in comparison with patients with tumors without known activating hotspot mutations) starting at the lowest dose tested of 3 mg, thereby supporting higher potency for taselisib against -mutant tumors. .
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.